Bicara Therapeutics (NASDAQ:BCAX) Given “Overweight” Rating at Cantor Fitzgerald
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They currently have a $13.01 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 4.75% from the company’s current price. A number […]
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They currently have a $13.01 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 4.75% from the company’s current price. A number […]
